XML 48 R37.htm IDEA: XBRL DOCUMENT
v3.23.3

Note 7 - Research and Development Rebate Receivable (Details Textual) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended |
--- | --- | --- | ---
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | Dec. 31, 2022
Research and Development Expense | $ 4,467 | $ 5,160 | $ 11,680 | $ 10,097 |
Research and Development Tax Rebate Receivable | 28 |  | 28 |  | $ 743
Atossa Genetics AUS Pty Ltd [Member] |  |  |  |  |
Research and Development Rebates Collected Would be Recalled With Penalties | 2,275 |  |  |  |
Research and Development Expense | 12 | 486 | 98 | 1,415 |
Research and Development Cash Rebate | 713 | 448 | 713 | 1,011 |
Research and Development Tax Rebate Receivable | 28 |  | 28 |  | $ 743
Research and Development Expense, Reduced Amount Due to Tax Rebate | $ 4 | $ 263 | $ 27 | $ 763 |

X
- Definition The amount of research and development cash rebate. + References No definition available. + Details
Name: | atos_ResearchAndDevelopmentCashRebate
Namespace Prefix: | atos_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Reduced amount of R&D expense by tax rebate. + References No definition available. + Details
Name: | atos_ResearchAndDevelopmentExpenseReducedAmountDueToTaxRebate
Namespace Prefix: | atos_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of research and development rebates collected would be recalled with penalties. + References No definition available. + Details
Name: | atos_ResearchAndDevelopmentRebatesCollectedWouldBeRecalledWithPenalties
Namespace Prefix: | atos_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Represents the value of research and development tax rebate receivable. + References No definition available. + Details
Name: | atos_ResearchAndDevelopmentTaxRebateReceivable
Namespace Prefix: | atos_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | srt_ConsolidatedEntitiesAxis=atos_AtossaGeneticsAUSPtyLtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |